| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1c89ce4d9ac03f9acd8ddede1162f94d |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P7-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D471-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D519-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D487-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P15-10 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-522 |
| filingDate |
2009-11-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2013-04-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_482db3b8c7352abeb2cacd682ca18c65
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_65afc9b70751a0508eecdf00deba9eef
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f7e5dedff7171f636a38cc6f43d6bee2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f00a38fe479e95c968c594c476111900
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_91c9f40224add38bd8db6dcfebc2c146
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a9fbd46a4eb709e437c4681563d5adf8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f868262866a8b71438d1d10d8132359a |
| publicationDate |
2013-04-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
AU-2009322836-B2 |
| titleOfInvention |
Soluble guanylate cyclase activators |
| abstract |
Compounds of Formula I are capable of modulating the body's production of cyclic guanosine monophosphate ("cGMP") and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of the Formula I, to their use for the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical preparations which comprise compounds of the Formula I. |
| priorityDate |
2008-11-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |